The company's market value has risen by 36% so far this year and by 32% throughout 2024. It is expected to become the world's most valuable pharmaceutical company in 2023.
According to Jared Holtz from Mizuho Securities, "They're now twice as valuable as the second-largest company in the healthcare sector by market cap. Lilly is in a fantastic position."
By the end of October, Eli Lilly released its third-quarter financial results, which revealed a 5.8-fold increase in net profit and a 50% rise in revenue.
One of the company's most popular drugs is Zepbound, which is used for weight loss. In May, clinical trials showed that using Zepbound allows patients to reduce abdominal fat more quickly than using Wegovy, a drug developed by competitor Novo Nordisk.
source: bloomberg.com
According to Jared Holtz from Mizuho Securities, "They're now twice as valuable as the second-largest company in the healthcare sector by market cap. Lilly is in a fantastic position."
By the end of October, Eli Lilly released its third-quarter financial results, which revealed a 5.8-fold increase in net profit and a 50% rise in revenue.
One of the company's most popular drugs is Zepbound, which is used for weight loss. In May, clinical trials showed that using Zepbound allows patients to reduce abdominal fat more quickly than using Wegovy, a drug developed by competitor Novo Nordisk.
source: bloomberg.com
